Galiximab

DB04901InvestigationalProtein Based Therapies

Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

Mechanism: Galiximab, an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques.
Curator reviewed
Primary indication: Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.Curator reviewed
Also known as: Anti-CD80 monoclonal antibody
Code names: IDEC-114

Resolves to

Compound

Targets

What you can answer from here — as of February 21, 2021

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

420Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Galiximab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.